Can – and Should – Pharma Manufacturing Heed Calls to Come Home?

The COVID-19 pandemic underscored weaknesses in critical industries in the U.S. In the pharmaceutical industry, the global nature of the business, long considered a benefit, became not just a weakness but a national security threat.

Now political leaders of both parties are calling for manufacturing in critical industries to return to the U.S. The question for pharma is whether it will comply.